Navigation Links
Scientists Identify Key Gene That Protects Against Leukemia
Date:4/8/2009

Researchers have identified a gene that controls the rapid production and differentiation of the stem cells that produce all blood cell types -- a discovery that could eventually open the door to more streamlined treatments for leukemia and other blood cancers, in which blood cells proliferate out of control.

(Vocus) April 8, 2009 -- Researchers have identified a gene that controls the rapid production and differentiation of the stem cells that produce all blood cell types -- a discovery that could eventually open the door to more streamlined treatments for leukemia and other blood cancers, in which blood cells proliferate out of control.

Additionally, in investigating the mechanisms of this gene, the scientists uncovered evidence that could lead to a protocol for bone marrow transplants that could boost the chance of a cure in some patients.

The research, led by Emmanuelle Passegué, PhD, of the University of California, San Francisco, demonstrates that the JunB gene is at the center of a complex network of molecular and environmental signals that regulate the proliferation and differentiation of hematopoietic stem cells, the multipotent, self-renewing cells that give rise to all blood cell types.
   
In the study published April 7, 2009, in the journal Cancer Cell, Passegué's team studied the behavior of JunB-deficient HSCs in both the culture dish and when transplanted into mice. In every case in which engraftment of the HSCs occurred in the mice, the scientists noted a progressive expansion of the myeloid lineage, which constitutes a type of mature white blood cell that fights infection. This expansion led by 6 to 12 months post-transplantation to the development of a myeloproliferative disease, which can evolve to leukemia. The finding indicated that the proliferating JunB-deficient HSCs causes leukemia.
   
Like traffic lights, which limit speed, direct the flow of vehicles and prevent accidents, JunB curtails both the rate at which HSCs are proliferating and the rate of differentiation toward the myeloid lineage that ultimately results in leukemia. The striking analogy inspired the image for the cover of Cancer Cell's April 7 issue.

Without JunB, HSCs lose their ability to respond to signals from the protein receptors Notch and TGF-beta, which reside on the cells' surface and play critical roles in determining cell fate.

"By uncovering this mechanism, we might one day be able to determine the difference between normal HSCs and leukemic stem cells in gene regulatory networks. This could allow us to develop more targeted therapies. These kinds of therapeutic applications are still down the road, but they can happen very quickly in the blood/leukemia field," says Passegué.

Passegué's study represents a turnabout from other research, which has demonstrated that mutated HSC that cause leukemia burn out at a faster rate than normal HSCs. In contrast, this study shows that JunB does not effect the cells' potential for unlimited self-renewal.

The researchers demonstrated this by treating both JunB-deficient mice and control mice with the powerful chemotherapy drug 5-FU, which was given to deplete regenerating HSCs. As expected, JunB-deficient mice consistently displayed higher levels of myeloid lineage than the control group, indicating constant regeneration of a myeloproliferative disease from JunB-deficient HSCs that persisted after treatment. When researchers compared survival rates of the animals during several cycles of treatment, they found little difference between the two groups, indicating that JunB-deficient HSCs do not exhaust faster than the control HSCs.

In tracking the differences between the JunB-deficient mice and the control group, it became apparent to the researchers that purity of HSCs was a key factor in determining the success of engraftment. Initially, the scientists were struck by the disparity in engraftment between the JunB-deficient HSCs and the control HSCs. But with the use of SLAM cells, a highly purified HSC population, they found that the two groups displayed in fact identical engraftment.

This finding may have important ramifications for patients undergoing bone marrow transplants, for leukemia, lymphoma, multiple myeloma and certain cancers.

"Currently, patients undergoing bone marrow transplants may not be getting enough of the quiescent transplanted HSCs that are optimal for successful engraftment," says Passegué. Using a highly purified HSC population could be more beneficial."

Senior author Passegué and first author Marianne Santaguida, PhD, are from the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF. Co-authors from the same center are Koen Schepers, PhD, and Bryan King.

Other co-authors are Benjamin Braun, MD, PhD, and Amit Sabnis, MD, of the UCSF Department of Pediatrics; E. Camilla Forsberg, PhD, of the Institute for Biology of Stem Cells at University of California, Santa Cruz, and Joanne Attema, PhD, of the Institute for Experimental Medical Science at Lund University, Sweden.

Research was funded by grants from the Concern Foundation, UCSF Research Evaluation and Allocation Committee and the NIH.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. For further information, visit http://www.ucsf.edu.

For more information about the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF, see http://irm.ucsf.edu/.

###

Read the full story at http://www.prweb.com/releases/JunB_Gene/Leukemia/prweb2310774.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium
2. Scientists Now Warn That White Wine Can Lead To Teeth Staining
3. Scientists Uncover New Weapon Against Huntingtons
4. Scientists show how a neuron gets its shape
5. Neuroscientists demonstrate link between brainwave acticity and visual perception
6. Einstein scientists propose new theory of autism
7. International Scientists Secure Quality in Molecular Diagnostics
8. CSHL neuroscientists propose project to comprehensively map mammalian brain circuits
9. Scientists Identify More Breast Cancer Genes
10. Scientists Capture HIV Transfer Among T-Cells on Video
11. 2 NYU scientists named Howard Hughes Medical Institutes Early Career Scientists
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists Identify Key Gene That Protects Against Leukemia 
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Venture Construction ... Classic Tournament held on June 20th at the Woodmont Country Club at 1201 ... Wings, an organization dedicated to helping service members that have been wounded in battle ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
Breaking Medicine Technology: